Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Integrated positron-emission tomography/computed tomography (PET/CT) with 2-[fluorine-18] fluoro-2-deoxy-D-glucose (FDG) is now established in the management of oncology patients. With increasing availability and a constantly advancing body of evidence, the role of FDG PET/CT in oesophageal cancer is set to expand to include initial staging, assessment of disease response, therapy planning, and detection of disease recurrence. This article reviews the utility of FDG PET/CT in the management of oesophageal carcinoma, discussing its role and limitations in the imaging of these patients.

Original publication




Journal article


Clin Radiol

Publication Date





1297 - 1309


Carcinoma, Esophageal Neoplasms, Female, Fluorodeoxyglucose F18, Humans, Male, Neoplasm Invasiveness, Neoplasm Staging, Positron-Emission Tomography, Radiopharmaceuticals, Tomography, Emission-Computed, Whole Body Imaging